misidentified by the laboratory. SCV S. aureus may cause persistent and recurrent infections and may have novel mechanisms for antibiotic resistance. 7 While there have been previous reports of CO 2 -dependent S. aureus, to our knowledge, this is the first reported case of a CO 2 -dependent PVL-producing MRSA. 8 -13 Recognition of this variant by laboratories can be achieved by incubation in both O 2 -and CO 2 -containing atmospheres.
Sir, HIV patients easily develop clinical visceral leishmaniasis (VL) caused by Leishmania infantum due to their inability to eliminate the parasite, while VL itself promotes evolution towards AIDS. Pentavalent antimonials (Sb V ) remain the first-line treatment option in HIV-positive patients, but with higher drug toxicity and treatment failure compared with immunocompetent patients. 1 Secondary prophylaxis is frequently adopted to prevent relapses; however, prolonged drug pressure is feared to select for drug resistance and HIV co-infected patients may therefore constitute an insidious reservoir for primary Sb resistance expansion in endemic areas, where dogs are generally considered as a zoonotic reservoir. 2 In this study, we specifically investigated the in vitro drug susceptibility phenotype of Brazilian L. infantum (syn. Leishmania chagasi) isolates from HIV-positive and HIV-negative patients with clinical VL before initiation of antileishmanial therapy. Isolates from eight HIV-positive and six HIV-negative patients, all typed as L. infantum zymodeme IOC/Z1, were obtained from the IOC-FIOCRUZ Leishmania collection (http://www.fiocruz.br/ioc/cgi/cgilua.exe/sys/start. htm?sid=197). The isolates had been obtained from VL patients and deposited based on written informed consent. The in vitro Sb III and Sb V susceptibility of intracellular amastigotes was determined as previously described. 3 At least four independent replicate tests were performed on each isolate. The activity 4 Each PCR product was digested using HaeIII and RsaI restriction enzymes, and fragments were visualized after gel electrophoresis.
Various drug susceptibility phenotypes were identified ( 5, 6 We noted a clear trend for a higher proportion of Sb V -resistant isolates among HIV-positive patients (7/9 Sb V -resistant isolates versus 2/6 among HIV-negative patients), but a considerably larger sample size would be required to confirm the significance of this difference.
Our results demonstrate the occurrence of primary Sb V -resistant L. infantum isolates among the two categories of VL patients. The existence of this phenomenon among HIVpositive patients can best be explained by the anthroponotic transmission suggested to occur among them. 7 This is supported here by the observation of identical kDNA-RFLP patterns in four isolates that were collected from three different HIV-positive patients over a time period of 4 years in Mato Grosso do Sul, Brazil, two of them originating from the same patient before and after treatment (Table 1 ). This contrasts with the unique patterns observed for all of the other isolates. On the other hand, the occurrence of primary resistance in HIV-negative patients is normally not expected in the context of zoonotic L. infantum. A similar observation was already made in Leishmania braziliensis 6 and could be explained by domestication of the natural transmission cycle or anthroponization through the vicinity of HIV-positive patients. Resistant strains could also be acquired from dogs previously exposed to antimonials. In Brazil, treatment of dogs with human medications is officially prohibited, but unauthorized use is not a rare situation.
Taking all observations together, our results clearly highlight the need for epidemiological monitoring of L. infantum antimony (Sb III and Sb V ) resistance in HIV-positive and HIV-negative patients, to better understand the dynamics of the emergence and spread of this phenomenon. Similarly, particular emphasis should be put on the follow-up of treatment outcome in patients infected with the different phenotypes, as observed here. On the one hand, the therapeutic efficacy of Sb V may theoretically not be hampered, since Sb V becomes reduced to the active Sb III , 8 to which most isolates were still susceptible; on the other hand, the relation between in vitro susceptibility phenotype and treatment outcome still needs to be substantiated in many more patients and locations. Previous studies in Leishmania donovani and L. braziliensis already indicated that the relationship between treatment outcome and in vitro drug resistance is not necessarily straightforward. 3, 5, 6 In the case of L. infantum, the zoonotic reservoir in dogs should be considered as well. 
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